Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Jump to section
- Article
- Abstract
- Measurement Techniques
- Response Criteria
- Comparison of Diameter and Volumetric Approaches
- Choosing a Measurable Lesion in Clinical Trials
- Technical Considerations
- Timing of Imaging Studies and Confirmation of Response
- Validity of Imaging End Points in Clinical Trials
- Challenges with Novel Therapeutics
- Conclusions
- Footnotes
- References
- Figures & Data
- Info & Metrics
- Responses
- References
Related Articles
Cited By...
- Automated Detection and Segmentation of Brain Metastases in Malignant Melanoma: Evaluation of a Dedicated Deep Learning Model
- "Early Imaging Marker of Progressive Glioblastoma: a window of opportunity"
- Tumor Response Assessment in Diffuse Intrinsic Pontine Glioma: Comparison of Semiautomated Volumetric, Semiautomated Linear, and Manual Linear Tumor Measurement Strategies
- Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial
- MR Fingerprinting of Adult Brain Tumors: Initial Experience
- Can an 18F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
- A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
- Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
- Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors